An Updated Review of Genetic Associations With Severe Adverse Drug Reactions: Translation and Implementation of Pharmacogenomic Testing in Clinical Practice

Adverse drug reactions (ADR) remain the major problems in healthcare. Most severe ADR are unpredictable, dose-independent and termed as type B idiosyncratic reactions. Recent pharmacogenomic studies have demonstrated the strong associations between severe ADR and genetic markers, including specific...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 13; p. 886377
Main Authors Wang, Chuang-Wei, Preclaro, Ivan Arni C., Lin, Wei-Hsiang, Chung, Wen-Hung
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 25.04.2022
Subjects
adverse drug reactions
CYP
drug transporter
drug-induced liver injury
human leukocyte antigens
Pharmacology
stevens-johnson syndrome
drug-induced liver injury
adverse drug reactions
stevens-johnson syndrome
human leukocyte antigens
CYP
drug transporter
toxic epidermal necrolysis
Online AccessGet full text

Cover

Abstract Adverse drug reactions (ADR) remain the major problems in healthcare. Most severe ADR are unpredictable, dose-independent and termed as type B idiosyncratic reactions. Recent pharmacogenomic studies have demonstrated the strong associations between severe ADR and genetic markers, including specific HLA alleles (e.g., HLA-B*15:02/HLA-B*57:01/HLA-A*31:01 for carbamazepine-induced severe cutaneous adverse drug reactions [SCAR], HLA-B*58:01 for allopurinol-SCAR, HLA-B*57:01 for abacavir-hypersensitivity, HLA-B*13:01 for dapsone/co-trimoxazole-induced SCAR, and HLA-A*33:01 for terbinafine-induced liver injury), drug metabolism enzymes (such as CYP2C9*3 for phenytoin-induced SCAR and missense variant of TPMT / NUDT15 for thiopurine-induced leukopenia), drug transporters (e.g., SLCO1B1 polymorphism for statin-induced myopathy), and T cell receptors (Sulfanilamide binding into the CDR3/Vα of the TCR 1.3). This mini review article aims to summarize the current knowledge of pharmacogenomics of severe ADR, and the potentially clinical use of these genetic markers for avoidance of ADR.
AbstractList Adverse drug reactions (ADR) remain the major problems in healthcare. Most severe ADR are unpredictable, dose-independent and termed as type B idiosyncratic reactions. Recent pharmacogenomic studies have demonstrated the strong associations between severe ADR and genetic markers, including specific HLA alleles (e.g., HLA-B*15:02/HLA-B*57:01/HLA-A*31:01 for carbamazepine-induced severe cutaneous adverse drug reactions [SCAR], HLA-B*58:01 for allopurinol-SCAR, HLA-B*57:01 for abacavir-hypersensitivity, HLA-B*13:01 for dapsone/co-trimoxazole-induced SCAR, and HLA-A*33:01 for terbinafine-induced liver injury), drug metabolism enzymes (such as CYP2C9*3 for phenytoin-induced SCAR and missense variant of TPMT/NUDT15 for thiopurine-induced leukopenia), drug transporters (e.g., SLCO1B1 polymorphism for statin-induced myopathy), and T cell receptors (Sulfanilamide binding into the CDR3/Vα of the TCR 1.3). This mini review article aims to summarize the current knowledge of pharmacogenomics of severe ADR, and the potentially clinical use of these genetic markers for avoidance of ADR.Adverse drug reactions (ADR) remain the major problems in healthcare. Most severe ADR are unpredictable, dose-independent and termed as type B idiosyncratic reactions. Recent pharmacogenomic studies have demonstrated the strong associations between severe ADR and genetic markers, including specific HLA alleles (e.g., HLA-B*15:02/HLA-B*57:01/HLA-A*31:01 for carbamazepine-induced severe cutaneous adverse drug reactions [SCAR], HLA-B*58:01 for allopurinol-SCAR, HLA-B*57:01 for abacavir-hypersensitivity, HLA-B*13:01 for dapsone/co-trimoxazole-induced SCAR, and HLA-A*33:01 for terbinafine-induced liver injury), drug metabolism enzymes (such as CYP2C9*3 for phenytoin-induced SCAR and missense variant of TPMT/NUDT15 for thiopurine-induced leukopenia), drug transporters (e.g., SLCO1B1 polymorphism for statin-induced myopathy), and T cell receptors (Sulfanilamide binding into the CDR3/Vα of the TCR 1.3). This mini review article aims to summarize the current knowledge of pharmacogenomics of severe ADR, and the potentially clinical use of these genetic markers for avoidance of ADR.
Adverse drug reactions (ADR) remain the major problems in healthcare. Most severe ADR are unpredictable, dose-independent and termed as type B idiosyncratic reactions. Recent pharmacogenomic studies have demonstrated the strong associations between severe ADR and genetic markers, including specific HLA alleles (e.g., HLA-B*15:02/HLA-B*57:01/HLA-A*31:01 for carbamazepine-induced severe cutaneous adverse drug reactions [SCAR], HLA-B*58:01 for allopurinol-SCAR, HLA-B*57:01 for abacavir-hypersensitivity, HLA-B*13:01 for dapsone/co-trimoxazole-induced SCAR, and HLA-A*33:01 for terbinafine-induced liver injury), drug metabolism enzymes (such as CYP2C9*3 for phenytoin-induced SCAR and missense variant of TPMT/NUDT15 for thiopurine-induced leukopenia), drug transporters (e.g., SLCO1B1 polymorphism for statin-induced myopathy), and T cell receptors (Sulfanilamide binding into the CDR3/Vα of the TCR 1.3). This mini review article aims to summarize the current knowledge of pharmacogenomics of severe ADR, and the potentially clinical use of these genetic markers for avoidance of ADR.
Adverse drug reactions (ADR) remain the major problems in healthcare. Most severe ADR are unpredictable, dose-independent and termed as type B idiosyncratic reactions. Recent pharmacogenomic studies have demonstrated the strong associations between severe ADR and genetic markers, including specific HLA alleles (e.g., for carbamazepine-induced severe cutaneous adverse drug reactions [SCAR], for allopurinol-SCAR, for abacavir-hypersensitivity, for dapsone/co-trimoxazole-induced SCAR, and for terbinafine-induced liver injury), drug metabolism enzymes (such as for phenytoin-induced SCAR and missense variant of / for thiopurine-induced leukopenia), drug transporters (e.g., SLCO1B1 polymorphism for statin-induced myopathy), and T cell receptors (Sulfanilamide binding into the CDR3/Vα of the TCR 1.3). This mini review article aims to summarize the current knowledge of pharmacogenomics of severe ADR, and the potentially clinical use of these genetic markers for avoidance of ADR.
Adverse drug reactions (ADR) remain the major problems in healthcare. Most severe ADR are unpredictable, dose-independent and termed as type B idiosyncratic reactions. Recent pharmacogenomic studies have demonstrated the strong associations between severe ADR and genetic markers, including specific HLA alleles (e.g., HLA-B*15:02/HLA-B*57:01/HLA-A*31:01 for carbamazepine-induced severe cutaneous adverse drug reactions [SCAR], HLA-B*58:01 for allopurinol-SCAR, HLA-B*57:01 for abacavir-hypersensitivity, HLA-B*13:01 for dapsone/co-trimoxazole-induced SCAR, and HLA-A*33:01 for terbinafine-induced liver injury), drug metabolism enzymes (such as CYP2C9*3 for phenytoin-induced SCAR and missense variant of TPMT / NUDT15 for thiopurine-induced leukopenia), drug transporters (e.g., SLCO1B1 polymorphism for statin-induced myopathy), and T cell receptors (Sulfanilamide binding into the CDR3/Vα of the TCR 1.3). This mini review article aims to summarize the current knowledge of pharmacogenomics of severe ADR, and the potentially clinical use of these genetic markers for avoidance of ADR.
Author Lin, Wei-Hsiang
Preclaro, Ivan Arni C.
Chung, Wen-Hung
Wang, Chuang-Wei
AuthorAffiliation 3 Chang Gung Immunology Consortium , Chang Gung Memorial Cital and Chang Gung University , Taoyuan , Taiwan
5 College of Medicine , Chang Gung University , Taoyuan , Taiwan
7 Department of Dermatology , Beijing Tsinghua Chang Gung Hospital , School of Clinical Medicine , Tsinghua University , Beijing , China
9 Genomic Medicine Core Laboratory , Chang Gung Memorial Hospital , Linkou , Taiwan
4 Department of Dermatology , Xiamen Chang Gung Hospital , Xiamen , China
8 Department of Dermatology , Ruijin Hospital , School of Medicine , Shanghai Jiao Tong University , Shanghai , China
2 Cancer Vaccine and Immune Cell Therapy Core Laboratory , Chang Gung Memorial Hospital , Linkou , Taiwan
6 Whole-Genome Research Core Laboratory of Human Diseases , Chang Gung Memorial Hospital , Keelung , Taiwan
1 Department of Dermatology , Drug Hypersensitivity Clinical and Research Center , Chang Gung Memorial Hospital , Taipei and Keelung , Taiwan
AuthorAffiliation_xml – name: 3 Chang Gung Immunology Consortium , Chang Gung Memorial Cital and Chang Gung University , Taoyuan , Taiwan
– name: 6 Whole-Genome Research Core Laboratory of Human Diseases , Chang Gung Memorial Hospital , Keelung , Taiwan
– name: 8 Department of Dermatology , Ruijin Hospital , School of Medicine , Shanghai Jiao Tong University , Shanghai , China
– name: 7 Department of Dermatology , Beijing Tsinghua Chang Gung Hospital , School of Clinical Medicine , Tsinghua University , Beijing , China
– name: 1 Department of Dermatology , Drug Hypersensitivity Clinical and Research Center , Chang Gung Memorial Hospital , Taipei and Keelung , Taiwan
– name: 5 College of Medicine , Chang Gung University , Taoyuan , Taiwan
– name: 2 Cancer Vaccine and Immune Cell Therapy Core Laboratory , Chang Gung Memorial Hospital , Linkou , Taiwan
– name: 9 Genomic Medicine Core Laboratory , Chang Gung Memorial Hospital , Linkou , Taiwan
– name: 4 Department of Dermatology , Xiamen Chang Gung Hospital , Xiamen , China
Author_xml – sequence: 1
  givenname: Chuang-Wei
  surname: Wang
  fullname: Wang, Chuang-Wei
– sequence: 2
  givenname: Ivan Arni C.
  surname: Preclaro
  fullname: Preclaro, Ivan Arni C.
– sequence: 3
  givenname: Wei-Hsiang
  surname: Lin
  fullname: Lin, Wei-Hsiang
– sequence: 4
  givenname: Wen-Hung
  surname: Chung
  fullname: Chung, Wen-Hung
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35548363$$D View this record in MEDLINE/PubMed
BookMark eNp1ksFuEzEQhleoiJbSB-CCfOSSYO_sem0OSFEKJVIlKkjF0XK848TVrh3sTRDvwsPiZFvUIuHLWOP5v5nxzMvixAePRfGa0SmAkO_sdqPjtKRlORWCQ9M8K84Y5zCRgpUnj-6nxUVKdzQfkBJ49aI4hbquBHA4K37PPLndtnrAlnzFvcOfJFhyhR4HZ8gspWCcHlzwiXx3w4Z8wz1GJLM2m4TkMu7WWafNMeQ9WUbtU3cUEO1bsui3Hfboh9GV0Te56l6bsEYf-pxiiWlwfk2cJ_POeWd0R27iAWjwVfHc6i7hxb09L24_fVzOP0-uv1wt5rPrial4PUxqhqatV1a3kgpg0sqat4YyLaAyjSw5R1ZRCwC2lmjB0MYCM8CwZEYaAefFYuS2Qd-pbXS9jr9U0E4dHSGulY65oA6VwZWFRq5KaJuKMyGyFbXWNTCgkjeZ9WFkbXerHluTe4-6ewJ9-uLdRq3DXuXaWR5XBry9B8TwY5d_R_UuGew67THsksrtVILSmh9C3zzO9TfJw3hzQDMGmBhSimiVceMocmrXKUbVYZfUcZfUYZfUuEtZyf5RPsD_r_kD-5nP_Q
CitedBy_id crossref_primary_10_1016_j_xgen_2024_100591
crossref_primary_10_3389_fphar_2022_959321
crossref_primary_10_1002_jcph_2213
crossref_primary_10_3390_ph16111596
crossref_primary_10_3389_fphar_2023_1183491
crossref_primary_10_3390_jpm14060649
crossref_primary_10_1002_cpt_2716
crossref_primary_10_3390_genes16030265
crossref_primary_10_1093_toxsci_kfae046
crossref_primary_10_53529_2500_1175_2024_3_31_41
crossref_primary_10_2217_pgs_2022_0132
crossref_primary_10_3390_ijms24087329
crossref_primary_10_3390_jcm12144576
crossref_primary_10_1016_j_jid_2022_07_035
crossref_primary_10_1080_09205063_2024_2431426
crossref_primary_10_1097_FPC_0000000000000517
crossref_primary_10_1186_s40364_024_00591_z
crossref_primary_10_1038_s41392_023_01619_w
crossref_primary_10_4103_JPDS_JPDS_38_24
crossref_primary_10_1080_03036758_2024_2406824
crossref_primary_10_2147_IDR_S402267
crossref_primary_10_3389_fphar_2022_954596
crossref_primary_10_3390_molecules28020621
Cites_doi 10.1111/epi.12564
10.1016/j.ejca.2020.07.019
10.1056/NEJMoa0801936
10.1097/00130832-200410000-00013
10.3389/fphar.2020.00969
10.1111/epi.12217
10.21037/tgh.2017.11.16
10.1038/jid.2015.165
10.1038/clpt.2011.287
10.1002/hep.31258
10.1146/annurev.pharmtox.47.120505.105150
10.1038/jhg.2016.10
10.1001/jamadermatol.2013.4114
10.3899/jrheum.151476
10.1038/tpj.2016.10
10.1111/j.1528-1167.2008.01719.x
10.1038/428486a
10.1056/NEJM199411103311906
10.1097/00008571-200406000-00002
10.1093/hmg/ddq537
10.1056/NEJMoa0706135
10.1001/jama.2010.1543
10.1001/jama.2014.7859
10.1038/tpj.2015.43
10.1038/clpt.2009.252
10.1111/1346-8138.13430
10.2147/PGPM.S140700
10.1038/tpj.2013.40
10.2217/14622416.9.11.1617
10.1056/NEJMoa1008410
10.1681/ASN.2004100882
10.1038/jid.2013.192
10.1093/rheumatology/kex253
10.1016/j.jid.2018.02.004
10.2174/138920007780866807
10.1016/s1665-2681(19)31817-4
10.1073/pnas.0409500102
10.1097/ACI.0b013e3282370c5f
10.3389/fimmu.2021.661135
10.1136/annrheumdis-2014-205577
10.1001/jamadermatol.2018.5360
10.2217/pgs-2020-0041
10.1056/NEJMoa1013297
10.1038/s41467-019-11396-2
10.1016/j.jaci.2010.11.046
10.1197/j.aem.2005.06.027
10.1111/all.13821
10.4103/0976-500X.81905
10.1038/s41397-018-0054-0
10.1056/NEJMoa1009717
10.1111/bjd.12501
10.1038/nrd3028
10.1200/JCO.2014.59.4671
10.1097/01.gim.0000153664.65759.cf
10.1001/jamainternmed.2015.3536
10.1002/cpt.1071
10.1056/NEJM199512143332404
10.1080/17425255.2021.1854726
10.1016/s0300-483x(03)00247-6
10.1038/ng.379
10.4330/wjc.v3.i5.153
10.1038/ng.632
10.1016/s0140-6736(02)07873-x
10.1111/j.1528-1167.2010.02533.x
10.2217/pgs-2015-0006
10.1093/rheumatology/kel216a
10.1016/j.jid.2018.10.048
10.1158/1078-0432.CCR-15-2044
10.1080/03602530902843483
10.1097/JCP.0b013e3182905a8d
10.1016/j.jid.2016.02.808
10.1097/01.fpc.0000230416.82349.90
10.2165/11318030-000000000-00000
10.1097/FPC.0000000000000359
10.1111/apt.16137
10.1002/cpt.1557
10.3390/jpm8010001
10.1097/FPC.0b013e328330a3b8
10.1097/01.fpc.0000199500.46842.4a
10.1016/j.jaci.2020.08.003
10.1124/pr.58.3.6
10.1542/peds.2008-1923
10.1097/FPC.0b013e32834282b8
10.1053/j.gastro.2011.04.001
10.1097/MD.0000000000010301
10.1038/sj.jid.5701033
10.1002/cpt.1915
10.1111/ajco.13028
10.1097/FPC.0000000000000153
10.1212/WNL.0000000000001034
10.1016/S0140-6736(02)08158-8
10.1111/bjh.13518
10.1111/jdv.16924
10.1016/s0016-5085(99)70404-x
10.1016/j.clpt.2006.06.010
10.1056/NEJM199101173240306
10.1016/j.eplepsyres.2011.08.010
10.1016/j.euroneuro.2018.05.009
10.1053/j.gastro.2016.12.016
10.1016/j.jhep.2010.05.033
10.1038/nrneph.2011.74
10.1016/j.jid.2021.03.014
10.2217/pgs.14.69
10.1111/bjh.12665
10.1016/j.jaci.2015.03.019
10.1038/sj.mp.4001494
10.1097/FPC.0b013e3282f3ef9c
10.1136/bmj.329.7456.15
10.1186/s12911-015-0139-5
10.1038/s41439-019-0082-6
10.1111/j.1445-5994.2011.02567.x
10.1002/phar.1978
10.3390/ijms22126480
10.1111/bph.12598
10.1002/cpt.1190
10.1001/jama.2019.0709
10.1038/ng.3508
10.1056/NEJMoa1213096
10.1001/jamainternmed.2014.1427
10.1212/WNL.0000000000003453
10.1016/j.jns.2017.04.041
10.1016/j.gastro.2005.05.006
10.1016/S0140-6736(02)11203-7
10.1002/acr.21772
10.1007/s00210-006-0040-y
10.2174/1389200219666180523095355
10.1212/WNL.0000000000004008
10.1016/j.clinthera.2021.03.008
10.1016/j.jaci.2011.08.013
10.1007/s11096-013-9777-9
10.1146/annurev.med.56.082103.104724
10.1001/jama.2009.1232
10.1172/JCI93349
10.1097/FPC.0b013e32831d0faf
10.1016/j.jaci.2019.01.045
10.3389/fphar.2018.00460
10.2165/00002018-200730110-00003
10.1038/jid.2012.510
10.1111/jcpt.13334
10.5414/ALX01508E
10.4103/0378-6323.57718
10.1016/j.jid.2019.12.025
10.1007/s12016-014-8418-y
10.1016/j.jsps.2013.02.003
10.1016/j.ajhg.2020.08.008
ContentType Journal Article
Copyright Copyright © 2022 Wang, Preclaro, Lin and Chung.
Copyright © 2022 Wang, Preclaro, Lin and Chung. 2022 Wang, Preclaro, Lin and Chung
Copyright_xml – notice: Copyright © 2022 Wang, Preclaro, Lin and Chung.
– notice: Copyright © 2022 Wang, Preclaro, Lin and Chung. 2022 Wang, Preclaro, Lin and Chung
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3389/fphar.2022.886377
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

PubMed

CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Wang et al
EISSN 1663-9812
ExternalDocumentID oai_doaj_org_article_cebf379b23d7461883d785aa53130967
PMC9081981
35548363
10_3389_fphar_2022_886377
Genre Journal Article
Review
GrantInformation_xml – fundername: ;
  grantid: 110-2320-B-182A-014-MY3 110-2326-B-182A-003-
– fundername: ;
  grantid: CORPG3J0321-3 CORPG1J0011-3
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
O5R
O5S
OK1
P2P
PGMZT
RNS
RPM
IAO
IEA
IHR
IHW
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c465t-51ecd5bfad908319f956dc01a834c79266e140f333f59ef3c07f31c31e21c9c83
IEDL.DBID M48
ISSN 1663-9812
IngestDate Wed Aug 27 01:19:46 EDT 2025
Thu Aug 21 18:20:03 EDT 2025
Fri Jul 11 08:23:37 EDT 2025
Thu Jan 02 22:53:49 EST 2025
Thu Apr 24 23:04:14 EDT 2025
Tue Jul 01 03:28:02 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords drug-induced liver injury
adverse drug reactions
stevens-johnson syndrome
human leukocyte antigens
CYP
drug transporter
toxic epidermal necrolysis
Language English
License Copyright © 2022 Wang, Preclaro, Lin and Chung.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c465t-51ecd5bfad908319f956dc01a834c79266e140f333f59ef3c07f31c31e21c9c83
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
This article was submitted to Pharmacogenetics and Pharmacogenomics, a section of the journal Frontiers in Pharmacology
Reviewed by: Taisei Mushiroda, RIKEN Center for Integrative Medical Sciences (IMS), Japan
Edited by: Wojciech Miltyk, Medical University of Bialystok, Poland
Wichittra Tassaneeyakul, Khon Kaen University, Thailand
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fphar.2022.886377
PMID 35548363
PQID 2664800561
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_cebf379b23d7461883d785aa53130967
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9081981
proquest_miscellaneous_2664800561
pubmed_primary_35548363
crossref_citationtrail_10_3389_fphar_2022_886377
crossref_primary_10_3389_fphar_2022_886377
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-04-25
PublicationDateYYYYMMDD 2022-04-25
PublicationDate_xml – month: 04
  year: 2022
  text: 2022-04-25
  day: 25
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in pharmacology
PublicationTitleAlternate Front Pharmacol
PublicationYear 2022
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Donaldson (B35) 2010; 53
Zaïr (B144) 2016; 17
Roujeau (B102) 1994; 331
Amante (B4) 2009; 8
Fabbri (B37) 2018; 28
Ko (B62) 2011; 128
Hauser (B43) 2005; 16
Björnsson (B11) 2017; 2
Chen (B21) 2011; 364
Chung (B29) 2015; 135
Li (B72) 2021; 73
Ke (B56) 2017; 44
Tassaneeyakul (B121) 2010; 51
Levi (B71) 2009; 123
Chantarangsu (B18) 2009; 19
Lucena (B76) 2011; 141
Amstutz (B5) 2014; 55
Ozeki (B93) 2011; 20
Chakravarty (B15) 2008; 47
Krebs (B66) 2020; 107
Sridharan (B113) 2021; 46
Yuliwulandari (B143) 2016; 61
Sousa-Pinto (B112) 2015; 136
Andrade (B7) 2005; 129
Carr (B14) 2019; 106
Fei (B38) 2018; 97
Nebert (B89) 2002; 360
Wang (B132) 2018; 128
Hughes (B46) 2004; 14
Nakamura (B88) 2020; 140
Eichelbaum (B36) 2006; 57
Chung (B26) 2015; 74
Tassaneeyakul (B120) 2009; 19
Phillips (B97) 2011; 127
Sikka (B109) 2005; 12
Hautekeete (B44) 1999; 117
Konvinse (B65) 2019; 144
Shuldiner (B108) 2009; 302
B2
König (B64) 2006; 372
Budhiraja (B12) 2011; 7
Cheung (B24) 2013; 54
Tanaka (B118) 2015; 171
Crews (B32) 2012; 91
Xiang (B135) 2018; 18
Roujeau (B101) 1995; 333
Sekula (B106) 2013; 133
Chen (B19) 2021; 35
Kaniwa (B53) 2008; 9
Nicoletti (B91) 2017; 152
Yang (B138) 2014; 15
Sassolas (B104) 2010; 88
Lonjou (B75) 2008; 18
Tiamkao (B122) 2013; 35
Pan (B94) 2019; 10
Chang (B17) 2020; 11
Kang (B52) 2011; 21
Zhao (B147) 2021; 141
Zhou (B148) 2009; 41
Wang (B133) 2013; 133
Hung (B47) 2006; 16
Mehta (B82) 2009; 75
McCormack (B80) 2011; 364
Niemi (B92) 2006; 80
Group (B42) 2008; 359
Kim (B60) 2017; 378
Stephens (B115) 2021; 17
Su (B116) 2019; 105
Ueta (B125) 2019; 6
Turner (B124) 2020; 21
Yang (B140) 2018; 14
Walker (B130) 2019; 321
Mockenhaupt (B84) 2017; 1
Sukasem (B117) 2020; 108
Xu (B136) 2016; 22
Yip (B142) 2015; 48
Daly (B34) 2017; 8
Pasanen (B96) 2006; 16
Chen (B20) 2017; 88
Mockenhaupt (B85) 2008; 128
Luzzatto (B77) 2014; 164
Mockenhaupt (B86) 2019; 74
Shoshi (B107) 2015; 15
Kuna (B67) 2018; 19
Miao (B83) 2009; 3
Carnovale (B13) 2014; 174
Moriyama (B87) 2016; 48
Zhang (B146) 2013; 369
Khanna (B57) 2012; 64
Pirmohamed (B98) 2004; 329
Liu (B73) 2019; 155
Kardaun (B54) 2013; 169
Sim (B110) 2014; 171
Chang (B16) 2017; 17
Pirmohamed (B99) 2003; 192
Umapathy (B127) 2011; 2
Mallal (B79) 2008; 358
Singer (B111) 2010; 42
Gardiner (B40) 2006; 58
Zhu (B150) 2017; 37
Avallone (B8) 2014; 18
Chung (B31) 2016; 43
Alomar (B3) 2014; 22
Mallal (B78) 2002; 359
Kim (B58) 2011; 97
Kim (B59) 2013; 33
Kakuta (B50) 2016; 16
Chen (B23) 2014; 83
Chung (B27) 2007; 7
Abel (B1) 2008; 358
Kalgutkar (B51) 2007; 8
Locharernkul (B74) 2008; 49
Daly (B33) 2009; 41
Langer (B68) 2020; 138
Stäuble (B114) 2021; 22
Chen (B22) 2018; 138
Chung (B28) 2004; 428
Ke (B55) 2019; 29
Uetrecht (B126) 2007; 47
Genin (B41) 2014; 14
Fei (B39) 2018; 9
Kongpan (B63) 2015; 25
Sanderson (B103) 2005; 7
Yee (B141) 2021; 43
Paré (B95) 2010; 363
University (B128) 2017; 88
Yang (B139) 2015; 33
Zastrozhin (B145) 2017; 10
Beutler (B10) 1991; 324
Chung (B30) 2016; 43
Lee (B69) 2012; 42
Chung (B25) 2014; 312
Mega (B81) 2010; 304
Valeyrie-Allanore (B129) 2007; 30
Wang (B134) 2019; 105
Kirchheiner (B61) 2004; 9
Wang (B131) 2021; 147
Ando (B6) 2000; 60
Banerjee (B9) 2020; 52
Giacomini (B49) 2010; 9
Tsai (B123) 2019; 139
Satapornpong (B105) 2021; 12
Zhou (B149) 2009; 48
Hetherington (B45) 2002; 359
Lerch (B70) 2004; 4
Tangamornsuksan (B119) 2013; 149
Yang (B137) 2015; 175
Hung (B48) 2005; 102
Plumpton (B100) 2017; 56
Ng (B90) 2016; 136
References_xml – volume: 358
  start-page: 2515
  year: 2008
  ident: B1
  article-title: Abacavir Hypersensitivity
  publication-title: N. Engl. J. Med.
– volume: 55
  start-page: 496
  year: 2014
  ident: B5
  article-title: Recommendations for HLA-B*15:02 and HLA-A*31:01 Genetic Testing to Reduce the Risk of Carbamazepine-Induced Hypersensitivity Reactions
  publication-title: Epilepsia
  doi: 10.1111/epi.12564
– volume: 60
  start-page: 6921.
  year: 2000
  ident: B6
  article-title: Polymorphisms of UDP-Glucuronosyltransferase Gene and Irinotecan Toxicity: a Pharmacogenetic Analysis
  publication-title: Cancer Res.
– volume: 138
  start-page: 212
  year: 2020
  ident: B68
  article-title: Usefulness of Current Candidate Genetic Markers to Identify Childhood Cancer Patients at Risk for Platinum-Induced Ototoxicity: Results of the European PanCareLIFE Cohort Study
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2020.07.019
– volume: 359
  start-page: 789
  year: 2008
  ident: B42
  article-title: SLCO1B1 Variants and Statin-Induced Myopathy-Aa Genomewide Study
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa0801936
– volume: 4
  start-page: 411
  year: 2004
  ident: B70
  article-title: The Immunological and Clinical Spectrum of Delayed Drug-Induced Exanthems
  publication-title: Curr. Opin. Allergy Clin. Immunol.
  doi: 10.1097/00130832-200410000-00013
– volume: 11
  start-page: 969
  year: 2020
  ident: B17
  article-title: Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2020.00969
– volume: 54
  start-page: 1307
  year: 2013
  ident: B24
  article-title: HLA-B Alleles Associated with Severe Cutaneous Reactions to Antiepileptic Drugs in Han Chinese
  publication-title: Epilepsia
  doi: 10.1111/epi.12217
– volume: 2
  start-page: 114
  year: 2017
  ident: B11
  article-title: Mortality Associated with Drug-Induced Liver Injury (DILI)
  publication-title: Transl Gastroenterol. Hepatol.
  doi: 10.21037/tgh.2017.11.16
– volume: 135
  start-page: 2237
  year: 2015
  ident: B29
  article-title: Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions
  publication-title: J. Invest. Dermatol.
  doi: 10.1038/jid.2015.165
– volume: 91
  start-page: 321
  year: 2012
  ident: B32
  article-title: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1038/clpt.2011.287
– volume: 73
  start-page: 268
  year: 2021
  ident: B72
  article-title: Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated with Trimethoprim-Sulfamethoxazole Induced Liver Injury
  publication-title: Hepatology
  doi: 10.1002/hep.31258
– volume: 47
  start-page: 513
  year: 2007
  ident: B126
  article-title: Idiosyncratic Drug Reactions: Current Understanding
  publication-title: Annu. Rev. Pharmacol. Toxicol.
  doi: 10.1146/annurev.pharmtox.47.120505.105150
– volume: 61
  start-page: 533
  year: 2016
  ident: B143
  article-title: NAT2 Variants Are Associated with Drug-Induced Liver Injury Caused by Anti-tuberculosis Drugs in Indonesian Patients with Tuberculosis
  publication-title: J. Hum. Genet.
  doi: 10.1038/jhg.2016.10
– volume: 149
  start-page: 1025
  year: 2013
  ident: B119
  article-title: Relationship between the HLA-B*1502 Allele and Carbamazepine-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: a Systematic Review and Meta-Analysis
  publication-title: JAMA Dermatol.
  doi: 10.1001/jamadermatol.2013.4114
– volume: 44
  start-page: 835
  year: 2017
  ident: B56
  article-title: Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions
  publication-title: J. Rheumatol.
  doi: 10.3899/jrheum.151476
– volume: 17
  start-page: 170
  year: 2017
  ident: B16
  article-title: Association of HLA-B*15:13 and HLA-B*15:02 with Phenytoin-Induced Severe Cutaneous Adverse Reactions in a Malay Population
  publication-title: Pharmacogenomics J.
  doi: 10.1038/tpj.2016.10
– volume: 49
  start-page: 2087
  year: 2008
  ident: B74
  article-title: Carbamazepine and Phenytoin Induced Stevens-Johnson Syndrome Is Associated with HLA-B*1502 Allele in Thai Population
  publication-title: Epilepsia
  doi: 10.1111/j.1528-1167.2008.01719.x
– volume: 428
  start-page: 486
  year: 2004
  ident: B28
  article-title: Medical Genetics: a Marker for Stevens-Johnson Syndrome
  publication-title: Nature
  doi: 10.1038/428486a
– volume: 331
  start-page: 1272
  year: 1994
  ident: B102
  article-title: Severe Adverse Cutaneous Reactions to Drugs
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJM199411103311906
– volume: 14
  start-page: 335
  year: 2004
  ident: B46
  article-title: Cost-effectiveness Analysis of HLA B*5701 Genotyping in Preventing Abacavir Hypersensitivity
  publication-title: Pharmacogenetics
  doi: 10.1097/00008571-200406000-00002
– volume: 20
  start-page: 1034
  year: 2011
  ident: B93
  article-title: Genome-wide Association Study Identifies HLA-A*3101 Allele as a Genetic Risk Factor for Carbamazepine-Induced Cutaneous Adverse Drug Reactions in Japanese Population
  publication-title: Hum. Mol. Genet.
  doi: 10.1093/hmg/ddq537
– volume: 358
  start-page: 568
  year: 2008
  ident: B79
  article-title: HLA-B*5701 Screening for Hypersensitivity to Abacavir
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa0706135
– volume: 304
  start-page: 1821
  year: 2010
  ident: B81
  article-title: Reduced-function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated with Clopidogrel Predominantly for PCI: a Meta-Analysis
  publication-title: JAMA
  doi: 10.1001/jama.2010.1543
– volume: 312
  start-page: 525
  year: 2014
  ident: B25
  article-title: Genetic Variants Associated with Phenytoin-Related Severe Cutaneous Adverse Reactions
  publication-title: JAMA
  doi: 10.1001/jama.2014.7859
– volume: 16
  start-page: 280
  year: 2016
  ident: B50
  article-title: NUDT15 R139C Causes Thiopurine-Induced Early Severe Hair Loss and Leukopenia in Japanese Patients with IBD
  publication-title: Pharmacogenomics J.
  doi: 10.1038/tpj.2015.43
– volume: 88
  start-page: 60
  year: 2010
  ident: B104
  article-title: ALDEN, an Algorithm for Assessment of Drug Causality in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison with Case-Control Analysis
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1038/clpt.2009.252
– volume: 43
  start-page: 758
  year: 2016
  ident: B31
  article-title: Severe Cutaneous Adverse Drug Reactions
  publication-title: J. Dermatol.
  doi: 10.1111/1346-8138.13430
– volume: 10
  start-page: 209
  year: 2017
  ident: B145
  article-title: Pharmacodynamic Genetic Polymorphisms Affect Adverse Drug Reactions of Haloperidol in Patients with Alcohol-Use Disorder
  publication-title: Pharmgenomics Pers Med.
  doi: 10.2147/PGPM.S140700
– volume: 14
  start-page: 281
  year: 2014
  ident: B41
  article-title: HLA-A*31:01 and Different Types of Carbamazepine-Induced Severe Cutaneous Adverse Reactions: an International Study and Meta-Analysis
  publication-title: Pharmacogenomics J.
  doi: 10.1038/tpj.2013.40
– volume: 9
  start-page: 1617
  year: 2008
  ident: B53
  article-title: HLA-B Locus in Japanese Patients with Anti-epileptics and Allopurinol-Related Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
  publication-title: Pharmacogenomics
  doi: 10.2217/14622416.9.11.1617
– volume: 363
  start-page: 1704
  year: 2010
  ident: B95
  article-title: Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1008410
– ident: B2
– volume: 16
  start-page: 1501
  year: 2005
  ident: B43
  article-title: ABCB1 Genotype of the Donor but Not of the Recipient Is a Major Risk Factor for Cyclosporine-Related Nephrotoxicity after Renal Transplantation
  publication-title: J. Am. Soc. Nephrol.
  doi: 10.1681/ASN.2004100882
– volume: 133
  start-page: 2642
  year: 2013
  ident: B133
  article-title: Association between HLA-B*1301 and Dapsone-Induced Hypersensitivity Reactions Among Leprosy Patients in China
  publication-title: J. Invest. Dermatol.
  doi: 10.1038/jid.2013.192
– volume: 18
  start-page: 165
  year: 2014
  ident: B8
  article-title: Azathioprine Treatment in Inflammatory Bowel Disease Patients: Type and Time of Onset of Side Effects
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 56
  start-page: 1729
  year: 2017
  ident: B100
  article-title: Cost Effectiveness Analysis of HLA-B*58:01 Genotyping Prior to Initiation of Allopurinol for Gout
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/kex253
– volume: 138
  start-page: 1546
  year: 2018
  ident: B22
  article-title: The Function of HLA-B*13:01 Involved in the Pathomechanism of Dapsone-Induced Severe Cutaneous Adverse Reactions
  publication-title: J. Invest. Dermatol.
  doi: 10.1016/j.jid.2018.02.004
– volume: 8
  start-page: 407
  year: 2007
  ident: B51
  article-title: Mechanism-based Inactivation of Cytochrome P450 Enzymes: Chemical Mechanisms, Structure-Activity Relationships and Relationship to Clinical Drug-Drug Interactions and Idiosyncratic Adverse Drug Reactions
  publication-title: Curr. Drug Metab.
  doi: 10.2174/138920007780866807
– volume: 43
  start-page: 758
  year: 2016
  ident: B30
  article-title: Severe Cutaneous Adverse Drug Reactions
  publication-title: J. Dermatol.
  doi: 10.1111/1346-8138.13430
– volume: 8
  start-page: 75
  year: 2009
  ident: B4
  article-title: Dress Syndrome and Fulminant Hepatic Failure Induced by Lamotrigine
  publication-title: Ann. Hepatol.
  doi: 10.1016/s1665-2681(19)31817-4
– volume: 102
  start-page: 4134
  year: 2005
  ident: B48
  article-title: HLA-B*5801 Allele as a Genetic Marker for Severe Cutaneous Adverse Reactions Caused by Allopurinol
  publication-title: Proc. Natl. Acad. Sci. U S A.
  doi: 10.1073/pnas.0409500102
– volume: 7
  start-page: 317
  year: 2007
  ident: B27
  article-title: Human Leukocyte Antigens and Drug Hypersensitivity
  publication-title: Curr. Opin. Allergy Clin. Immunol.
  doi: 10.1097/ACI.0b013e3282370c5f
– volume: 12
  start-page: 661135
  year: 2021
  ident: B105
  article-title: HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.661135
– volume: 74
  start-page: 2157
  year: 2015
  ident: B26
  article-title: Insights into the Poor Prognosis of Allopurinol-Induced Severe Cutaneous Adverse Reactions: the Impact of Renal Insufficiency, High Plasma Levels of Oxypurinol and Granulysin
  publication-title: Ann. Rheum. Dis.
  doi: 10.1136/annrheumdis-2014-205577
– volume: 155
  start-page: 666
  year: 2019
  ident: B73
  article-title: Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients with Leprosy
  publication-title: JAMA Dermatol.
  doi: 10.1001/jamadermatol.2018.5360
– volume: 21
  start-page: 821
  year: 2020
  ident: B124
  article-title: Pharmacogenetics and Statin-Related Myopathy: what Do We Know?
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs-2020-0041
– volume: 364
  start-page: 1134
  year: 2011
  ident: B80
  article-title: HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1013297
– volume: 10
  start-page: 3569
  year: 2019
  ident: B94
  article-title: Identification of Drug-specific Public TCR Driving Severe Cutaneous Adverse Reactions
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-019-11396-2
– volume: 127
  start-page: S60
  year: 2011
  ident: B97
  article-title: Drug Hypersensitivity: Pharmacogenetics and Clinical Syndromes
  publication-title: J. Allergy Clin. Immunol.
  doi: 10.1016/j.jaci.2010.11.046
– volume: 12
  start-page: 1227
  year: 2005
  ident: B109
  article-title: Bench to Bedside: Pharmacogenomics, Adverse Drug Interactions, and the Cytochrome P450 System
  publication-title: Acad. Emerg. Med.
  doi: 10.1197/j.aem.2005.06.027
– volume: 74
  start-page: 2227
  year: 2019
  ident: B86
  article-title: HLA-B*57:01 Confers Genetic Susceptibility to Carbamazepine-Induced SJS/TEN in Europeans
  publication-title: Allergy
  doi: 10.1111/all.13821
– volume: 2
  start-page: 114
  year: 2011
  ident: B127
  article-title: HLA Involvement in Nevirapine-Induced Dermatological Reaction in Antiretroviral-Treated HIV-1 Patients
  publication-title: J. Pharmacol. Pharmacother.
  doi: 10.4103/0976-500X.81905
– volume: 18
  start-page: 721
  year: 2018
  ident: B135
  article-title: Association between SLCO1B1 T521C Polymorphism and Risk of Statin-Induced Myopathy: a Meta-Analysis
  publication-title: Pharmacogenomics J.
  doi: 10.1038/s41397-018-0054-0
– volume: 364
  start-page: 1126
  year: 2011
  ident: B21
  article-title: Carbamazepine-induced Toxic Effects and HLA-B*1502 Screening in Taiwan
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1009717
– volume: 169
  start-page: 1071
  year: 2013
  ident: B54
  article-title: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): an Original Multisystem Adverse Drug Reaction. Results from the Prospective RegiSCAR Study
  publication-title: Br. J. Dermatol.
  doi: 10.1111/bjd.12501
– volume: 9
  start-page: 215.
  year: 2010
  ident: B49
  article-title: Membrane Transporters in Drug Development
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/nrd3028
– volume: 33
  start-page: 1235
  year: 2015
  ident: B139
  article-title: Inherited NUDT15 Variant Is a Genetic Determinant of Mercaptopurine Intolerance in Children with Acute Lymphoblastic Leukemia
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2014.59.4671
– volume: 7
  start-page: 97
  year: 2005
  ident: B103
  article-title: CYP2C9 Gene Variants, Drug Dose, and Bleeding Risk in Warfarin-Treated Patients: a HuGEnet Systematic Review and Meta-Analysis
  publication-title: Genet. Med.
  doi: 10.1097/01.gim.0000153664.65759.cf
– volume: 175
  start-page: 1550
  year: 2015
  ident: B137
  article-title: Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan
  publication-title: JAMA Intern. Med.
  doi: 10.1001/jamainternmed.2015.3536
– volume: 105
  start-page: 112
  year: 2019
  ident: B134
  article-title: The Medication Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Asians: The Major Drug Causality and Comparison with the US FDA Label
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1002/cpt.1071
– volume: 333
  start-page: 1600
  year: 1995
  ident: B101
  article-title: Medication Use and the Risk of Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJM199512143332404
– volume: 17
  start-page: 153
  year: 2021
  ident: B115
  article-title: Genetic Risk Factors in the Development of Idiosyncratic Drug-Induced Liver Injury
  publication-title: Expert Opin. Drug Metab. Toxicol.
  doi: 10.1080/17425255.2021.1854726
– volume: 192
  start-page: 23
  year: 2003
  ident: B99
  article-title: Cytochrome P450 Enzyme Polymorphisms and Adverse Drug Reactions
  publication-title: Toxicology
  doi: 10.1016/s0300-483x(03)00247-6
– volume: 41
  start-page: 816
  year: 2009
  ident: B33
  article-title: HLA-B*5701 Genotype Is a Major Determinant of Drug-Induced Liver Injury Due to Flucloxacillin
  publication-title: Nat. Genet.
  doi: 10.1038/ng.379
– volume: 3
  start-page: 2250.
  year: 2009
  ident: B83
  article-title: Cytochrome P-450 Polymorphisms and Response to Clopidogrel
  publication-title: N. Engl. J. Med.
  doi: 10.4330/wjc.v3.i5.153
– volume: 42
  start-page: 711
  year: 2010
  ident: B111
  article-title: A Genome-wide Study Identifies HLA Alleles Associated with Lumiracoxib-Related Liver Injury
  publication-title: Nat. Genet.
  doi: 10.1038/ng.632
– volume: 359
  start-page: 727
  year: 2002
  ident: B78
  article-title: Association between Presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and Hypersensitivity to HIV-1 Reverse-Transcriptase Inhibitor Abacavir
  publication-title: Lancet
  doi: 10.1016/s0140-6736(02)07873-x
– volume: 51
  start-page: 926
  year: 2010
  ident: B121
  article-title: Association between HLA-B*1502 and Carbamazepine-Induced Severe Cutaneous Adverse Drug Reactions in a Thai Population
  publication-title: Epilepsia
  doi: 10.1111/j.1528-1167.2010.02533.x
– volume: 17
  start-page: 1089
  year: 2016
  ident: B144
  article-title: Efflux Transporter Variants as Predictors of Drug Toxicity in Lung Cancer Patients: Systematic Review and Meta-Analysis
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs-2015-0006
– volume: 47
  start-page: 924
  year: 2008
  ident: B15
  article-title: BSR/BHPR Guideline for Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy in Consultation with the British Association of Dermatologists
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/kel216a
– volume: 139
  start-page: 1722
  year: 2019
  ident: B123
  article-title: Increased Type 2 Innate Lymphoid Cells in Patients with Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome
  publication-title: J. Invest. Dermatol.
  doi: 10.1016/j.jid.2018.10.048
– volume: 22
  start-page: 1371
  year: 2016
  ident: B136
  article-title: HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-15-2044
– volume: 41
  start-page: 89
  year: 2009
  ident: B148
  article-title: Polymorphism of Human Cytochrome P450 Enzymes and its Clinical Impact
  publication-title: Drug Metab. Rev.
  doi: 10.1080/03602530902843483
– volume: 33
  start-page: 491
  year: 2013
  ident: B59
  article-title: ABCB1 c.2677G>T Variation Is Associated with Adverse Reactions of OROS-Methylphenidate in Children and Adolescents with ADHD
  publication-title: J. Clin. Psychopharmacol.
  doi: 10.1097/JCP.0b013e3182905a8d
– volume: 136
  start-page: 1373
  year: 2016
  ident: B90
  article-title: Impact of the HLA-B(*)58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions
  publication-title: J. Invest. Dermatol.
  doi: 10.1016/j.jid.2016.02.808
– volume: 16
  start-page: 873
  year: 2006
  ident: B96
  article-title: SLCO1B1 Polymorphism Markedly Affects the Pharmacokinetics of Simvastatin Acid
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/01.fpc.0000230416.82349.90
– volume: 48
  start-page: 689
  year: 2009
  ident: B149
  article-title: Polymorphism of Human Cytochrome P450 2D6 and its Clinical Significance: Part I
  publication-title: Clin. Pharmacokinet.
  doi: 10.2165/11318030-000000000-00000
– volume: 29
  start-page: 1
  year: 2019
  ident: B55
  article-title: Utility of Human Leukocyte Antigen-B*58: 01 Genotyping and Patient Outcomes
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0000000000000359
– volume: 52
  start-page: 1683
  year: 2020
  ident: B9
  article-title: NUDT15 C415T Variant Compared with TPMT Genotyping in Predicting Azathioprine-Induced Leucopenia: Prospective Analysis of 1014 Inflammatory Bowel Disease Patients in India
  publication-title: Aliment. Pharmacol. Ther.
  doi: 10.1111/apt.16137
– volume: 106
  start-page: 1353
  year: 2019
  ident: B14
  article-title: Genomewide Association Study of Statin-Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1002/cpt.1557
– volume: 8
  year: 2017
  ident: B34
  article-title: Pharmacogenomics of CYP2C9: Functional and Clinical Considerations
  publication-title: J. Pers Med.
  doi: 10.3390/jpm8010001
– volume: 19
  start-page: 704
  year: 2009
  ident: B120
  article-title: Strong Association between HLA-B*5801 and Allopurinol-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in a Thai Population
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0b013e328330a3b8
– volume: 16
  start-page: 297
  year: 2006
  ident: B47
  article-title: Genetic Susceptibility to Carbamazepine-Induced Cutaneous Adverse Drug Reactions
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/01.fpc.0000199500.46842.4a
– volume: 147
  start-page: 1402
  year: 2021
  ident: B131
  article-title: Whole Genome Sequencing Identifies Genetic Variants Associated with Co-trimoxazole Hypersensitivity in Asians
  publication-title: J. Allergy Clin. Immunol.
  doi: 10.1016/j.jaci.2020.08.003
– volume: 58
  start-page: 521
  year: 2006
  ident: B40
  article-title: Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
  publication-title: Pharmacol. Rev.
  doi: 10.1124/pr.58.3.6
– volume: 123
  start-page: e297
  year: 2009
  ident: B71
  article-title: Medications as Risk Factors of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children: a Pooled Analysis
  publication-title: Pediatrics
  doi: 10.1542/peds.2008-1923
– volume: 21
  start-page: 303
  year: 2011
  ident: B52
  article-title: Positive and Negative Associations of HLA Class I Alleles with Allopurinol-Induced SCARs in Koreans
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0b013e32834282b8
– volume: 141
  start-page: 338
  year: 2011
  ident: B76
  article-title: Susceptibility to Amoxicillin-Clavulanate-Induced Liver Injury Is Influenced by Multiple HLA Class I and II Alleles
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2011.04.001
– volume: 97
  start-page: e0301
  year: 2018
  ident: B38
  article-title: NUDT15 R139C Variation Increases the Risk of Azathioprine-Induced Toxicity in Chinese Subjects: Case Report and Literature Review
  publication-title: Medicine (Baltimore)
  doi: 10.1097/MD.0000000000010301
– volume: 128
  start-page: 35
  year: 2008
  ident: B85
  article-title: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Assessment of Medication Risks with Emphasis on Recently Marketed Drugs. The EuroSCAR-Study
  publication-title: J. Invest. Dermatol.
  doi: 10.1038/sj.jid.5701033
– volume: 108
  start-page: 1078
  year: 2020
  ident: B117
  article-title: Genetic Association of Co-trimoxazole-induced Severe Cutaneous Adverse Reactions Is Phenotype-specific: HLA Class I Genotypes and Haplotypes
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1002/cpt.1915
– volume: 14
  start-page: e479
  year: 2018
  ident: B140
  article-title: UGT1A1*6 and UGT1A1*28 Polymorphisms Are Correlated with Irinotecan-Induced Toxicity: A Meta-Analysis
  publication-title: Asia Pac. J. Clin. Oncol.
  doi: 10.1111/ajco.13028
– volume: 25
  start-page: 402
  year: 2015
  ident: B63
  article-title: Candidate HLA Genes for Prediction of Co-trimoxazole-induced Severe Cutaneous Reactions
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0000000000000153
– volume: 83
  start-page: 2077
  year: 2014
  ident: B23
  article-title: Effects of a HLA-B*15:02 Screening Policy on Antiepileptic Drug Use and Severe Skin Reactions
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000001034
– volume: 359
  start-page: 1121
  year: 2002
  ident: B45
  article-title: Genetic Variations in HLA-B Region and Hypersensitivity Reactions to Abacavir
  publication-title: Lancet
  doi: 10.1016/S0140-6736(02)08158-8
– volume: 171
  start-page: 109
  year: 2015
  ident: B118
  article-title: Susceptibility to 6-MP Toxicity Conferred by a NUDT15 Variant in Japanese Children with Acute Lymphoblastic Leukaemia
  publication-title: Br. J. Haematol.
  doi: 10.1111/bjh.13518
– volume: 35
  start-page: 712
  year: 2021
  ident: B19
  article-title: The Risk of Anti-osteoporotic Agent-Induced Severe Cutaneous Adverse Drug Reactions and Their Association with HLA
  publication-title: J. Eur. Acad. Dermatol. Venereol.
  doi: 10.1111/jdv.16924
– volume: 117
  start-page: 1181
  year: 1999
  ident: B44
  article-title: HLA Association of Amoxicillin-Clavulanate-Iinduced Hepatitis
  publication-title: Gastroenterology
  doi: 10.1016/s0016-5085(99)70404-x
– volume: 80
  start-page: 356
  year: 2006
  ident: B92
  article-title: SLCO1B1 Polymorphism and Sex Affect the Pharmacokinetics of Pravastatin but Not Fluvastatin
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1016/j.clpt.2006.06.010
– volume: 324
  start-page: 169
  year: 1991
  ident: B10
  article-title: Glucose-6-phosphate Dehydrogenase Deficiency
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJM199101173240306
– volume: 97
  start-page: 190
  year: 2011
  ident: B58
  article-title: Carbamazepine-induced Severe Cutaneous Adverse Reactions and HLA Genotypes in Koreans
  publication-title: Epilepsy Res.
  doi: 10.1016/j.eplepsyres.2011.08.010
– volume: 28
  start-page: 945
  year: 2018
  ident: B37
  article-title: Effect of Cytochrome CYP2C19 Metabolizing Activity on Antidepressant Response and Side Effects: Meta-Analysis of Data from Genome-wide Association Studies
  publication-title: Eur. Neuropsychopharmacol.
  doi: 10.1016/j.euroneuro.2018.05.009
– volume: 152
  start-page: 1078
  year: 2017
  ident: B91
  article-title: Association of Liver Injury from Specific Drugs, or Groups of Drugs, with Polymorphisms in HLA and Other Genes in a Genome-wide Association Study
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2016.12.016
– volume: 53
  start-page: 1049
  year: 2010
  ident: B35
  article-title: Human Leucocyte Antigen Class II Genotype in Susceptibility and Resistance to Co-amoxiclav-induced Liver Injury
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2010.05.033
– volume: 7
  start-page: 478
  year: 2011
  ident: B12
  article-title: Azathioprine-related Myelosuppression in a Patient Homozygous for TPMT*3A
  publication-title: Nat. Rev. Nephrol.
  doi: 10.1038/nrneph.2011.74
– volume: 141
  start-page: 2412
  year: 2021
  ident: B147
  article-title: HLA Class-II‒Restricted CD8+ T Cells Contribute to the Promiscuous Immune Response in Dapsone-Hypersensitive Patients
  publication-title: J. Invest. Dermatol.
  doi: 10.1016/j.jid.2021.03.014
– volume: 15
  start-page: 1461
  year: 2014
  ident: B138
  article-title: HLA-B*13:01 Is Associated with Salazosulfapyridine-Induced Drug Rash with Eosinophilia and Systemic Symptoms in Chinese Han Population
  publication-title: Pharmacogenomics
  doi: 10.2217/pgs.14.69
– volume: 164
  start-page: 469
  year: 2014
  ident: B77
  article-title: G6PD Deficiency: a Classic Example of Pharmacogenetics with On-Going Clinical Implications
  publication-title: Br. J. Haematol.
  doi: 10.1111/bjh.12665
– volume: 136
  start-page: 1092
  year: 2015
  ident: B112
  article-title: Pharmacogenetics of Abacavir Hypersensitivity: A Systematic Review and Meta-Analysis of the Association with HLA-B*57:01
  publication-title: J. Allergy Clin. Immunol.
  doi: 10.1016/j.jaci.2015.03.019
– volume: 9
  start-page: 442
  year: 2004
  ident: B61
  article-title: Pharmacogenetics of Antidepressants and Antipsychotics: the Contribution of Allelic Variations to the Phenotype of Drug Response
  publication-title: Mol. Psychiatry
  doi: 10.1038/sj.mp.4001494
– volume: 18
  start-page: 99
  year: 2008
  ident: B75
  article-title: A European Study of HLA-B in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Related to Five High-Risk Drugs
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0b013e3282f3ef9c
– volume: 329
  start-page: 15
  year: 2004
  ident: B98
  article-title: Adverse Drug Reactions as Cause of Admission to Hospital: Prospective Analysis of 18 820 Patients
  publication-title: BMJ
  doi: 10.1136/bmj.329.7456.15
– volume: 15
  start-page: 15
  year: 2015
  ident: B107
  article-title: GraphSAW: a Web-Based System for Graphical Analysis of Drug Interactions and Side Effects Using Pharmaceutical and Molecular Data
  publication-title: BMC Med. Inform. Decis. Mak
  doi: 10.1186/s12911-015-0139-5
– volume: 6
  start-page: 50
  year: 2019
  ident: B125
  article-title: Association of HLA Class I and II Gene Polymorphisms with Acetaminophen-Related Stevens-Johnson Syndrome with Severe Ocular Complications in Japanese Individuals
  publication-title: Hum. Genome
  doi: 10.1038/s41439-019-0082-6
– volume: 42
  start-page: 411
  year: 2012
  ident: B69
  article-title: Initiating Allopurinol Therapy: Do We Need to Know the Patient's Human Leucocyte Antigen Status?
  publication-title: Intern. Med. J.
  doi: 10.1111/j.1445-5994.2011.02567.x
– volume: 37
  start-page: 1089
  year: 2017
  ident: B150
  article-title: Serotonin Transporter Gene Polymorphisms and Selective Serotonin Reuptake Inhibitor Tolerability: Review of Pharmacogenetic Evidence
  publication-title: Pharmacotherapy
  doi: 10.1002/phar.1978
– volume: 22
  year: 2021
  ident: B114
  article-title: Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms22126480
– volume: 171
  start-page: 2705
  year: 2014
  ident: B110
  article-title: Arylamine N-Acetyltransferases: from Drug Metabolism and Pharmacogenetics to Drug Discovery
  publication-title: Br. J. Pharmacol.
  doi: 10.1111/bph.12598
– volume: 105
  start-page: 476
  year: 2019
  ident: B116
  article-title: HLA Alleles and CYP2C9*3 as Predictors of Phenytoin Hypersensitivity in East Asians
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1002/cpt.1190
– volume: 321
  start-page: 773
  year: 2019
  ident: B130
  article-title: Association of Genetic Variants in NUDT15 with Thiopurine-Induced Myelosuppression in Patients with Inflammatory Bowel Disease
  publication-title: JAMA
  doi: 10.1001/jama.2019.0709
– volume: 48
  start-page: 367
  year: 2016
  ident: B87
  article-title: NUDT15 Polymorphisms Alter Thiopurine Metabolism and Hematopoietic Toxicity
  publication-title: Nat. Genet.
  doi: 10.1038/ng.3508
– volume: 369
  start-page: 1620
  year: 2013
  ident: B146
  article-title: HLA-B*13:01 and the Dapsone Hypersensitivity Syndrome
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1213096
– volume: 174
  start-page: 1031
  year: 2014
  ident: B13
  article-title: Allopurinol Overuse in Asymptomatic Hyperuricemia: a Teachable Moment
  publication-title: JAMA Intern. Med.
  doi: 10.1001/jamainternmed.2014.1427
– volume: 88
  start-page: 78
  year: 2017
  ident: B20
  article-title: Risk and Association of HLA with Oxcarbazepine-Induced Cutaneous Adverse Reactions in Asians
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000003453
– volume: 378
  start-page: 64
  year: 2017
  ident: B60
  article-title: NUDT15 p.R139C Variant Is Common and Strongly Associated with Azathioprine-Induced Early Leukopenia and Severe Alopecia in Korean Patients with Various Neurological Diseases
  publication-title: J. Neurol. Sci.
  doi: 10.1016/j.jns.2017.04.041
– volume: 129
  start-page: 512
  year: 2005
  ident: B7
  article-title: Drug-induced Liver Injury: an Analysis of 461 Incidences Submitted to the Spanish Registry over a 10-year Period
  publication-title: Gastroenterology
  doi: 10.1016/j.gastro.2005.05.006
– volume: 360
  start-page: 1155
  year: 2002
  ident: B89
  article-title: Clinical Importance of the Cytochromes P450
  publication-title: Lancet
  doi: 10.1016/S0140-6736(02)11203-7
– volume: 64
  start-page: 1431
  year: 2012
  ident: B57
  article-title: 2012 American College of Rheumatology Guidelines for Management of Gout. Part 1: Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia
  publication-title: Arthritis Care Res. (Hoboken)
  doi: 10.1002/acr.21772
– volume: 372
  start-page: 432
  year: 2006
  ident: B64
  article-title: Pharmacogenomics of Human OATP Transporters
  publication-title: Naunyn Schmiedebergs Arch. Pharmacol.
  doi: 10.1007/s00210-006-0040-y
– volume: 19
  start-page: 830
  year: 2018
  ident: B67
  article-title: Models of Drug Induced Liver Injury (DILI) - Current Issues and Future Perspectives
  publication-title: Curr. Drug Metab.
  doi: 10.2174/1389200219666180523095355
– volume: 88
  start-page: 2018
  year: 2017
  ident: B128
  article-title: HLA Screening in Reducing the Risk of Antiepileptic Drug-Induced Cutaneous Adverse Reactions
  publication-title: HLA Associated Important Dis.
  doi: 10.1212/WNL.0000000000004008
– volume: 43
  start-page: 836
  year: 2021
  ident: B141
  article-title: Association between the CYP2C9 Genotype and Hypoglycemia Among Patients with Type 2 Diabetes Receiving Sulfonylurea Treatment: A Meta-Analysis
  publication-title: Clin. Ther.
  doi: 10.1016/j.clinthera.2021.03.008
– volume: 128
  start-page: 1266
  year: 2011
  ident: B62
  article-title: Shared and Restricted T-Cell Receptor Use Is Crucial for Carbamazepine-Induced Stevens-Johnson Syndrome
  publication-title: J. Allergy Clin. Immunol.
  doi: 10.1016/j.jaci.2011.08.013
– volume: 35
  start-page: 608
  year: 2013
  ident: B122
  article-title: Cost Minimization of HLA-B*1502 Screening before Prescribing Carbamazepine in Thailand
  publication-title: Int. J. Clin. Pharm.
  doi: 10.1007/s11096-013-9777-9
– volume: 57
  start-page: 119
  year: 2006
  ident: B36
  article-title: Pharmacogenomics and Individualized Drug Therapy
  publication-title: Annu. Rev. Med.
  doi: 10.1146/annurev.med.56.082103.104724
– volume: 302
  start-page: 849
  year: 2009
  ident: B108
  article-title: Association of Cytochrome P450 2C19 Genotype with the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
  publication-title: JAMA
  doi: 10.1001/jama.2009.1232
– volume: 128
  start-page: 985
  year: 2018
  ident: B132
  article-title: Randomized, Controlled Trial of TNF-α Antagonist in CTL-Mediated Severe Cutaneous Adverse Reactions
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI93349
– volume: 19
  start-page: 139
  year: 2009
  ident: B18
  article-title: HLA-B*3505 Allele Is a strong Predictor for Nevirapine-Induced Skin Adverse Drug Reactions in HIV-Infected Thai Patients
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0b013e32831d0faf
– volume: 144
  start-page: 183
  year: 2019
  ident: B65
  article-title: HLA-A*32:01 Is Strongly Associated with Vancomycin-Induced Drug Reaction with Eosinophilia and Systemic Symptoms
  publication-title: J. Allergy Clin. Immunol.
  doi: 10.1016/j.jaci.2019.01.045
– volume: 9
  start-page: 460
  year: 2018
  ident: B39
  article-title: NUDT15 R139C Variants Increase the Risk of Azathioprine-Induced Leukopenia in Chinese Autoimmune Patients
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2018.00460
– volume: 30
  start-page: 1011
  year: 2007
  ident: B129
  article-title: Drug-induced Skin, Nail and Hair Disorders
  publication-title: Drug Saf.
  doi: 10.2165/00002018-200730110-00003
– volume: 133
  start-page: 1197
  year: 2013
  ident: B106
  article-title: Comprehensive Survival Analysis of a Cohort of Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
  publication-title: J. Invest. Dermatol.
  doi: 10.1038/jid.2012.510
– volume: 46
  start-page: 640
  year: 2021
  ident: B113
  article-title: A Network Meta-Analysis of CYP2C9, CYP2C9 with VKORC1 and CYP2C9 with VKORC1 and CYP4F2 Genotype-Based Warfarin Dosing Strategies Compared to Traditional
  publication-title: J. Clin. Pharm. Ther.
  doi: 10.1111/jcpt.13334
– volume: 1
  start-page: 96
  year: 2017
  ident: B84
  article-title: Epidemiology of Cutaneous Adverse Drug Reactions
  publication-title: Allergol. Select
  doi: 10.5414/ALX01508E
– volume: 75
  start-page: 579
  year: 2009
  ident: B82
  article-title: Association of HLA-B*1502 Allele and Carbamazepine-Induced Stevens-Johnson Syndrome Among Indians
  publication-title: Indian J. Dermatol. Venereol. Leprol.
  doi: 10.4103/0378-6323.57718
– volume: 140
  start-page: 1659
  year: 2020
  ident: B88
  article-title: Association of HLA-A*11:01 with Sulfonamide-Related Severe Cutaneous Adverse Reactions in Japanese Patients
  publication-title: J. Invest. Dermatol.
  doi: 10.1016/j.jid.2019.12.025
– volume: 48
  start-page: 165
  year: 2015
  ident: B142
  article-title: Genetics of Immune-Mediated Adverse Drug Reactions: a Comprehensive and Clinical Review
  publication-title: Clin. Rev. Allergy Immunol.
  doi: 10.1007/s12016-014-8418-y
– volume: 22
  start-page: 83
  year: 2014
  ident: B3
  article-title: Factors Affecting the Development of Adverse Drug Reactions (Review Article)
  publication-title: Saudi Pharm. J.
  doi: 10.1016/j.jsps.2013.02.003
– volume: 107
  start-page: 612
  year: 2020
  ident: B66
  article-title: Genome-wide Study Identifies Association between HLA-B∗55:01 and Self-Reported Penicillin Allergy
  publication-title: Am. J. Hum. Genet.
  doi: 10.1016/j.ajhg.2020.08.008
SSID ssj0000399364
Score 2.419739
SecondaryResourceType review_article
Snippet Adverse drug reactions (ADR) remain the major problems in healthcare. Most severe ADR are unpredictable, dose-independent and termed as type B idiosyncratic...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 886377
SubjectTerms adverse drug reactions
CYP
drug transporter
drug-induced liver injury
human leukocyte antigens
Pharmacology
stevens-johnson syndrome
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Li9swEBZlT72Uvpu-mELZQ1mztiXZcm_bx7IUWgJN6N6MrMcmsKuEdXLY_9If2xnJySaltJeeDLZkCc0nz4xH8w1jb6XmJZe8zKxQLhNa6axTBveVktJaqU2p6X_H12_V2VR8OZfnO6W-6ExYogdOC3dsXOd53XQlt7WoCqXwqqTWiB2O5nfMI0edt-NMxW8w6d1KpDAmemHNsV_ONPF_liVio-J1vaeIIl__n4zM389K7iif0_vs3mA1wkma7QN2x4WH7HCcaKdvjmBym0XVH8EhjG8JqW8esZ8nAaZLcu0tpFgALDwQ4TS2hx0B9fBjvprBd4f4dhBrNfcOPl2vL7BfyoDo30NUb-kIHehgIRIMXw05TIFevRmeCGCvcIgJUXmEC5gHGHhIL2E8pGc9ZtPTz5OPZ9lQlSEzopKrTBbOWNl5bRuqUtZ49LCsyQutuDB1gwrfodPmOedeNs5zk9eeF4YXrixMYxR_wg7CIrhnDIxVaEBYr0Wnhcw73VX41kJaIwrN83LE8o2IWjNQllPljMsWXReSahul2pJU2yTVEXu37bJMfB1_a_yB5L5tSFTb8QYCsB0A2P4LgCP2ZoOaFrcmxVt0cIt13-JSCBW5VkfsaULRdigy8xSv-IjVe_jam8v-kzCfRfrvhqw4VTz_H5N_we7SelB4rJQv2cHqeu1eoZW16l7HDfULtwIodQ
  priority: 102
  providerName: Directory of Open Access Journals
Title An Updated Review of Genetic Associations With Severe Adverse Drug Reactions: Translation and Implementation of Pharmacogenomic Testing in Clinical Practice
URI https://www.ncbi.nlm.nih.gov/pubmed/35548363
https://www.proquest.com/docview/2664800561
https://pubmed.ncbi.nlm.nih.gov/PMC9081981
https://doaj.org/article/cebf379b23d7461883d785aa53130967
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Za9tAEF7SFEpeSu-4R9hCyUOJWkm7K60KpaRHCIUUQ22aN7HawzY4a9eyof4v_bGdWUlOXEwf-iSQ9hD7zezM7PENIa-EYikTLI0MlzbiSqqokhr0SgphjFA6VbjecfEtOx_yr5fico906a3aAax3hnaYT2q4mL759XP9ART-PUacYG_fuvlYIbVnmgLsGcvzW-Q2GKYc9fSi9fbDxIzGOOPN3ubumgfkDhpgyTK2ZagCn_8uJ_Tvs5Q3jNPZPXK39SrpaSMG98me9Q_Icb-hpV6f0MH1Lav6hB7T_jVh9foh-X3q6XCOob-hzV4BnTmKhNRQnt4AsKY_Jssx_W5B_i0NuZxrSz8vViOo19yQqN_RYP6aI3ZUeUMDAfFVe8fJY9Nd90gQewVdDJDqw4_oxNOWp3RK--31rUdkePZl8Ok8arM2RJpnYhmJxGojKqdMgVnMCgcRmNFxoiTjOi_AIbAQ1DnGmBOFdUzHuWOJZolNE11oyR6TfT_z9pBQbSTgaJzileIirlSVQauJMJonisVpj8QdRKVuKc0xs8a0hNAGAS4DwCUCXDYA98jrTZV5w-fxr8IfEfdNQaTiDi9mi1HZanapbeVYXlQpMznPEinhKYVSMLkxiA-hkZed1JSgurgfo7ydreoShoLLwMXaI08aKdp01Ulhj-Rb8rX1L9tf_GQc6MEL9PJk8vS_az4jBzgIuGeWiudkf7lY2Rfgei2ro7BkcRTU6g8mujMW
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=An+Updated+Review+of+Genetic+Associations+With+Severe+Adverse+Drug+Reactions%3A+Translation+and+Implementation+of+Pharmacogenomic+Testing+in+Clinical+Practice&rft.jtitle=Frontiers+in+pharmacology&rft.au=Wang%2C+Chuang-Wei&rft.au=Preclaro%2C+Ivan+Arni+C.&rft.au=Lin%2C+Wei-Hsiang&rft.au=Chung%2C+Wen-Hung&rft.date=2022-04-25&rft.pub=Frontiers+Media+S.A&rft.eissn=1663-9812&rft.volume=13&rft_id=info:doi/10.3389%2Ffphar.2022.886377&rft_id=info%3Apmid%2F35548363&rft.externalDocID=PMC9081981
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon